SCHEMBL404326

SCHEMBL404326

COc1ccc(COC2C(OC(C)=O)OC(COC(C)=O)C[C@H]2OCc2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
TSHR P16473 1/20 0.38
SSTR1 P30872 1/20 0.37
SSTR2 P30874 1/20 0.37
SSTR4 P31391 1/20 0.37
SSTR3 P32745 1/20 0.37
SSTR5 P35346 1/20 0.37
KCNA5 P22460 1/20 0.37
ALDH1A1 P00352 3/20 0.37
KMT2A Q03164 2/20 0.37
CYP2C19 P33261 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 4/20 0.37
MAPK1 P28482 2/20 0.37
FABP7 O15540 1/20 0.36
FABP5 Q01469 1/20 0.36
POLB P06746 1/20 0.36
CYP2C9 P11712 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL402676 0.90 LMNA (0.34) LMNASSTR1SSTR2SSTR4SSTR3
SCHEMBL402667 0.88 ALDH1A1 (0.39) TSHRKCNA5ALDH1A1CYP2C19CYP3A4
SCHEMBL402948 0.81 ALDH1A1 (0.41) KCNA5ALDH1A1KMT2ACYP2C19CYP3A4
SCHEMBL19976426 0.81 TSHR (0.45) LMNATSHRALDH1A1KMT2ACYP2C19
SCHEMBL13044308 0.80 TSHR (0.44) LMNATSHRALDH1A1KMT2ACYP2C19
SCHEMBL13044610 0.80 TSHR (0.44) LMNATSHRALDH1A1KMT2ACYP2C19
SCHEMBL19976412 0.78 LMNA (0.52) LMNATSHRALDH1A1KMT2ACYP2D6
SCHEMBL19976417 0.78 LMNA (0.50) LMNATSHRALDH1A1KMT2ACYP2D6
SCHEMBL14362881 0.77 LMNA (0.40) LMNATSHRALDH1A1KMT2ACYP2C19
SCHEMBL19789660 0.76 LMNA (0.41) LMNATSHRALDH1A1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF SANOFI-AVENTIS (FR) 2012-03-15 US disclosed
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof SANOFI-AVENTIS (FR) 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065153-A1 AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF HPSE, HAAO, HEXD LMNA 3944/4885TSHR 2387/4885SSTR1 1129/4885
US-20070270354-A1 Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof HPSE, HAAO, HEXD LMNA 3939/4885TSHR 2381/4885SSTR1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.